Veracyte Signs $150M M&A Deal with Convergent Genomics Inc.
Veracyte completed the acquisition of Convergent Genomics, a genomic diagnostics company focused on bladder cancer, for $150 million in upfront cash plus up to $30 million in milestone-based payments. The deal adds the UroAmp urinary tumor DNA (utDNA) technology to Veracyte's urology portfolio, with a commercial launch expected in late 2028.
- Value
- $150M
- Counterparty
- Convergent Genomics Inc.
“UroAmp brings a differentiated urine-based platform that is especially well suited to non-muscle-invasive disease. Together with our Decipher Bladder and TrueMRD tests, this acquisition strengthens Veracyte’s ability to deliver complementary insights from urine, tissue, and blood to help guide care across the bladder cancer continuum.”
Marc Stapley, Veracyte’s chief executive officer
“We believe this combination can help accelerate the development of new tools that give physicians greater confidence in treatment and monitoring decisions and can ultimately improve care for people living with bladder cancer.”
Brian Slingerland, chief executive officer, Convergent Genomics